Treatment failure with new hepatitis C drugs (Q37975543)

26 August 2017

Treatment failure with new hepatitis C drugs (English)

1 reference

26 August 2017

1 reference

3

Eva Poveda

1 reference

26 August 2017

1

Vincent Soriano

1 reference

26 August 2017

2

Eugenia Vispo

1 reference

26 August 2017

5

Pablo Barreiro

1 reference

26 August 2017

4

Pablo Labarga

1 reference

PubMed ID

22242928

26 August 2017

language of work or name

English

0 references

publication date

14 January 2012

1 reference

Expert Opinion on Pharmacotherapy

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

3

1 reference

26 August 2017

313-323

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

26 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Directly acting antivirals against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

A new era of hepatitis C therapy begins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Duration and fitness dependence of quasispecies memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Resistance to direct antiviral agents in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Hepatitis C virus resistance to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.653341

10.1517/14656566.2012.653341

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22242928